A5074572213- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Diet, Metabolism, and Disease
- Estrogen and related hormone effects
- Abdominal vascular conditions and treatments
- Gastrointestinal disorders and treatments
- Hepatitis B Virus Studies
- Gastric Cancer Management and Outcomes
- Cancer, Stress, Anesthesia, and Immune Response
- Liver physiology and pathology
- Biochemical Analysis and Sensing Techniques
- Colorectal Cancer Screening and Detection
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gut microbiota and health
- Liver Disease Diagnosis and Treatment
- Diverticular Disease and Complications
- Pancreatitis Pathology and Treatment
- Chemokine receptors and signaling
- Radiomics and Machine Learning in Medical Imaging
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
National Cheng Kung University Hospital
2019-2025
Zero to Three
2021
Infiltrative hepatocellular carcinoma (HCC) is often associated with an unfavorable prognosis, posing a challenge in determining the optimal therapeutic approach. Immunotherapy, employing immune checkpoint inhibitors (ICIs), has become preferred first-line treatment for advanced HCC. However, overall effectiveness of ICIs patients infiltrative HCC remains unclear. This study aims to compare effect ICI on clinical outcomes between and non-infiltrative A retrospective cohort consisting...
Delayed postpolypectomy bleeding occurs in approximately 1% to 2% of all patients undergoing colonoscopic polypectomy, and this rate increases 6% with large (>2 cm) colon polyps. Sucralfate can protect the mucosa promote its healing. This study was conducted investigate whether spraying sucralfate powder on polypectomy wounds prevent delayed postoperative bleeding. randomized controlled trial included polyps (size≥0.5cm) who had undergone at our hospital between May 2023 January 2024. After...
The presence of vascular invasion is associated with poor survival in advanced hepatocellular carcinoma (HCC). We compared the effectiveness hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs), alone or combination, patients HCC.We retrospectively reviewed medical records adult unresectable HCC macrovascular (MVI) who were treated HAIC ICIs combination at a single centre Taiwan. Overall tumour response, thrombi overall (OS) progression-free (PFS) 130...
Immune checkpoint inhibitors (ICIs) combined with multitarget tyrosine kinase (MTKIs) exert a synergistic effect and are effective in unresectable hepatocellular carcinoma (uHCC). However, precise data regarding the real-world clinical applications of these combination therapies uHCC lacking. This study compared treatment efficacy sorafenib versus lenvatinib programmed cell death protein-1 (PD-1) patients setting. Among 208 treated PD-1 inhibitors, 88 were administered ICIs or lenvatinib....
Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile these drugs still scarce. Thus, aims this study were to investigate differences in between nivolumab pembrolizumab unresectable HCC patients a real-world setting.A total 115 who received treatment with (n = 73) or 42) combination without tyrosine kinase was enrolled. Therapeutic response, survival outcomes, profiles compared among...
Acute pancreatitis is a common disease, but peripancreatic pseudoaneurysm rare. Bleeding from without connection to GI tract may delay treatment and cause mortality. Being aware of this rare complication after acute important. A 69-year-old woman was admitted our hospital with abdominal pain nausea for 2 days. Her vital signs were stable apart minor increase in temperature (37.1°C). Blood tests revealed an elevated serum lipase 2111 U/L normal hemoglobin 11.8 g/dl. She treated intravenous...
Abstract Sorafenib treatment is suggested for patients with intermediate‐stage hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). This study aimed if combining local‐regional sorafenib adds benefit who had tumor progression after three sessions of TACE within 12 months. We retrospectively analyzed the outcomes alone and combined therapies in HCC using inverse probability weighting (IPTW). Forty‐nine were enrolled; 28 treated alone, whereas 21 received or...